Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Ray, Kausik K.; Cannon, Christopher P.; McCabe, Carolyn H.; Cairns, Richard; Tonkin, Andrew M.; Sacks, Frank M.; Jackson, Graham; Braunwald, Eugene

doi:10.1016/j.jacc.2005.03.077

Cited by 356Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchAntiplatelet Therapy and Cardiovascular Diseases

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Open access

Ray, Kausik K., Cannon, Christopher P., McCabe, Carolyn H., Cairns, Richard, Tonkin, Andrew M., Sacks, Frank M., Jackson, Graham, Braunwald, Eugene·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.03.077

Open this paper in CoChat — free account Open PDF

Abstract

Objectives Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients.Background The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear.Methods A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months.Results The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003).Conclusions Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.03.077

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Data from specific trials and meta-analysis support routine early use of prompt and intensive statin therapy.
“Data from specific trials 23,30,35 and meta-analysis support routine early use of prompt and intensive statin therapy.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [35]
Data from specific trials and meta-analysis support routine early use of prompt, intensive, and prolonged statin therapy.
“Data from specific trials 358-360 and meta-analysis support routine early use of prompt, intensive and prolonged statin therapy.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [360]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · see citing works
Self-citation
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R. M., Frey, M. J., Lakkis, N. M., Neumann, F., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,093 · see citing works
Self-citation
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease.
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,658 · see citing works
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325 · see citing works
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001 · see citing works
Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation
Ray, K., & Cannon, C. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-004-0205-9 · Cited by 43 · see citing works
Self-citation

Flagged first, then by citations

Research works printed but not linked: 1

Kaplan-Meier estimates of the composite end point of death, myocardial infarction (MI), or rehospitalization with recurrent acute coronary syndrome (ACS) by statin treatment, in patients free from clinical events from six months to end of study. 1409 JACC Vol. 46, No. 8, 2005

Sorted by citations

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333 · see citing works
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,840 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
Untitled work
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,409 · see citing works
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227 · see citing works
Self-citation
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094 · see citing works
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 772 · see citing works
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Graham, I. M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.024 · Cited by 715 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 693 · see citing works
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688 · see citing works
The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment
Insull, W. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.013 · Cited by 637 · see citing works
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.038 · Cited by 610 · see citing works
Self-citation
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
Räber, L., Ueki, Y., Otsuka, T., Losdat, S., Häner, J. D., Lønborg, J., Fahrni, G., Iglesias, J. F., van Geuns, R., Ondracek, A. S., et al. (2022) · JAMA · doi:10.1001/jama.2022.5218 · Cited by 616 · see citing works
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 527 · see citing works
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G., Montinaro, A., & Sciascio, G. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.025 · Cited by 483 · see citing works
Coronary Microembolization
Heusch, G., Kleinbongard, P., Böse, D., Levkau, B., Haude, M., Schulz, R., & Erbel, R. (2009) · Circulation · doi:10.1161/circulationaha.109.888784 · Cited by 419 · see citing works
Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation
Tawakol, A. A., Fayad, Z. A., Mogg, R., Alon, A., Klimas, M. T., Dansky, H. M., Subramanian, S. S., Abdelbaky, A., Rudd, J. H. F., Farkouh, M. E., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.066 · Cited by 417 · see citing works
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 349 · see citing works
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 328 · see citing works
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rosselló, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 341 · see citing works
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 313 · see citing works
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Koskinas, K. C., Windecker, S., Pedrazzini, G., Mueller, C. E., Cook, S., Matter, C. M., Müller, O., Häner, J. D., Gencer, B., Crljenica, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.010 · Cited by 285 · see citing works
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 286 · see citing works
Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy
Kini, A. S., Baber, U., Kovacic, J. C., Limaye, A. M., Ali, Z. A., Sweeny, J. M., Maehara, A., Mehran, R., Dangas, G., Mintz, G. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.058 · Cited by 283 · see citing works
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863 · see citing works
Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation
Tang, J., Lobatto, M. E., Hassing, L., van der Staay, S. E. M., van Rijs, S. M., Calcagno, C., Braza, M. S., Baxter, S., Fay, F., Sánchez-Gaytán, B. L., et al. (2015) · Science Advances · doi:10.1126/sciadv.1400223 · Cited by 226 · see citing works
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 260 · see citing works
Statins as Antithrombotic Drugs
Violi, F., Calvieri, C., Ferro, D., & Pignatelli, P. (2013) · Circulation · doi:10.1161/circulationaha.112.145334 · Cited by 206 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192 · see citing works
Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women
Alexopoulos, N. A., Melek, B. H., Arepalli, C. D., Hartlage, G. R., Chen, Z., Kim, S., Stillman, A. E., & Raggi, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.051 · Cited by 184 · see citing works
Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers
Yasue, H., Mizuno, Y., Harada, E., Itoh, T., Nakagawa, H., Nakayama, M., Ogawa, H., Tayama, S., Honda, T., Hokimoto, S., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.049 · Cited by 179 · see citing works
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 180 · see citing works
Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem
Hayward, R. A., Hofer, T. P., & Vijan, S. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 164 · see citing works
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
Ganesan, A., Crum‐Cianflone, N. F., Higgins, J. M., Qin, J., Rehm, C. A., Metcalf, J. A., Brandt, C., Vita, J., Decker, C. F., Sklar, P. A., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq115 · Cited by 156 · see citing works
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007) · Heart · doi:10.1136/hrt.2006.112508 · Cited by 143 · see citing works
Cardiovascular effects of statins, beyond lipid-lowering properties
Mihos, C. G., Pineda, A. M., & Santana, O. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.009 · Cited by 143 · see citing works
2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Self-citation
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 118 · see citing works
Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Mannu, G., Zaman, M., Gupta, A., Rehman, H. U., & Myint, P. K. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076313 · Cited by 118 · see citing works
A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications
Oikonomou, E. K., Leopoulou, M., Theofilis, P., Antonopoulos, A. S., Siasos, G., Latsios, G., Mystakidi, V. C., Antoniades, C. A., & Tousoulis, D. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.027 · Cited by 111 · see citing works
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110 · see citing works
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
Banach, M., Penson, P. E., Vrablı́k, M., Bunc, M., Dyrbuś, K., Fedačko, J., Gaiță, D. I., Gierlotka, M. J., Járai, Z., Magda, S. L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105499 · Cited by 102 · see citing works
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 100 · see citing works
Impact of adherence to statins on coronary artery disease in primary prevention
Bouchard, M.-H., Dragomir, A., Blais, L., Bérard, A., Pilon, D., & Perreault, S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02828.x · Cited by 101 · see citing works
Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy
Hirayama, A., Saito, S., Ueda, Y., Takayama, T., Honye, J., Komatsu, S., Yamaguchi, O., Li, Y., Yajima, J., Nanto, S., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0755 · Cited by 97 · see citing works
Guía europea de prevención cardiovascular en la práctica clínica: Adaptación española del CEIPC 2008
Lobos, J., Royo-Bordonada, M. A., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano, Á., et al. (2008) · Revista Española de Salud Pública · doi:10.1590/s1135-57272008000600002 · Cited by 94 · see citing works
The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease
Mihos, C. G., Salas, M. J., & Santana, O. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181f52a7f · Cited by 95 · see citing works
Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy
Corrao, G., Conti, V., Merlino, L. G., Catapano, A. L., & Mancia, G. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.004 · Cited by 90 · see citing works
Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment
Merwick, Á., Albers, G. W., Arsava, E. M., Ay, H., Calvet, D., Coutts, S. B., Cucchiara, B. L., Demchuk, A. M., Giles, M. F., Mas, J.-L., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001576 · Cited by 89 · see citing works
Cellular and molecular mechanisms of statins: an update on pleiotropic effects
Satoh, M., Takahashi, Y., Tabuchi, T., Minami, Y., Tamada, M., Takahashi, K., Itoh, T., Morino, Y., & Nakamura, M. (2015) · Clinical Science · doi:10.1042/cs20150027 · Cited by 88 · see citing works
Low-Density Lipoprotein Cholesterol Level in Patients With Acute Myocardial Infarction Having Percutaneous Coronary Intervention (the Cholesterol Paradox)
Cho, K. H., Jeong, M. H., Ahn, Y., Kim, Y. J., Chae, S. C., Hong, T. J., Seong, I. W., Chae, J. K., Kim, C. J., Cho, M., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.009 · Cited by 86 · see citing works
Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.02.013 · Cited by 84 · see citing works
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
Gibson, C. M., Kastelein, J. J. P., Phillips, A. T., Aylward, P. E., Yee, M. K., Tendera, M., Nicholls, S. J., Pocock, S., Goodman, S. G., Alexander, J. H., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.052 · Cited by 84 · see citing works
Effect of Statin Therapy on Mortality in Patients With Peripheral Arterial Disease and Comparison of Those With Versus Without Associated Chronic Obstructive Pulmonary Disease
van Gestel, Y. R. B. M., Hoeks, S. E., Sin, D. D., Şimşek, C., Welten, G. M. J. M., Schouten, O., Stam, H. J., Mertens, F. W., van Domburg, R. T., & Poldermans, D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.038 · Cited by 83 · see citing works
Rapid Stabilization of Vulnerable Carotid Plaque Within 1 Month of Pitavastatin Treatment in Patients With Acute Coronary Syndrome
Nakamura, T., Obata, J., Kitta, Y., Takano, H., Kobayashi, T., Fujioka, D., Saitō, Y., Kodama, Y., Kawabata, K., Mende, A., et al. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318165dcad · Cited by 78 · see citing works
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial
Mehta, S. R., Paré, G., Lonn, E., Jolly, S. S., Natarajan, M. K., Pinilla‐Echeverri, N., Schwalm, J.-D., Sheth, T., Sibbald, M., Tsang, M., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-22-00735 · Cited by 76 · see citing works
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Zhao, S., Yu, B., Peng, D., & Huo, Y. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.003 · Cited by 76 · see citing works
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & D, E. B. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.016 · Cited by 72 · see citing works
Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall
Kajimoto, K., Miyauchi, K., Kasai, T., Shimada, K., Kojima, Y., Shimada, A., Niinami, H., Amano, A., & Daida, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.028 · Cited by 73 · see citing works
Plaque stabilization: Can we turn theory into evidence?
Libby, P., & Sasiela, W. (2006) · American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.017 · Cited by 82 · see citing works
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study
Płazak, W., Gryga, K., Dziedzic‐Oleksy, H., Pająk, L. T., Konieczyńska, M., Podolec, P. S., & Musiał, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3402 · Cited by 73 · see citing works
Pleiotropic Effects and Cholesterol-Lowering Therapy
Shaw, S. M., Fildes, J. E., Yonan, N. A., & Williams, S. G. (2008) · Cardiology · doi:10.1159/000137692 · Cited by 70 · see citing works
Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults With Limited Prior Drug Coverage
McWilliams, J. M., Zaslavsky, A. M., & Huskamp, H. A. (2011) · JAMA · doi:10.1001/jama.2011.1026 · Cited by 69 · see citing works
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
Larosa, J., Deedwania, P., Shepherd, J., Wenger, N., Greten, H., Demicco, D., & Breazna, A. (2010) · American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.025 · Cited by 69 · see citing works
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 64 · see citing works
Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?
Ray, K. K., Cannon, C. P., & Ganz, P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.016 · Cited by 65 · see citing works
Self-citation
Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry
Leósdóttir, M., Schubert, J. R., Brandts, J., Gustafsson, S., Cars, T., Sundström, J., Jernberg, T., Ray, K. K., & Hagström, E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.007 · Cited by 67 · see citing works
Self-citation
Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging
Lee, J., Wiesmann, F., Shirodaria, C. C., Leeson, P., Petersen, S. E., Francis, J. M., Jackson, C., Robson, M. D., Neubauer, S., Channon, K. M., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.001 · Cited by 62 · see citing works
Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness
Migrino, R. Q., Bowers, M. R., Harmann, L. M., Prost, R. W., & LaDisa, J. F. (2011) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-13-37 · Cited by 60 · see citing works
Atorvastatin reduces T ‐cell activation and exhaustion among HIV ‐infected c ART ‐treated suboptimal immune responders in U ganda: a randomised crossover placebo‐controlled trial
Nakanjako, D., Ssinabulya, I., Nabatanzi, R., Bayigga, L., Kiragga, A. N., Joloba, M. L., Kaleebu, P., Kambugu, A. D., Kamya, M. R., Sékaly, R., et al. (2014) · Tropical Medicine & International Health · doi:10.1111/tmi.12442 · Cited by 59 · see citing works
12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome
Yun, K. H., Oh, S. K., Rhee, S. J., Yoo, N. J., Kim, N., & Jeong, J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.052 · Cited by 59 · see citing works
The Cholesterol Paradox in Heart Failure
Velavan, P., Loh, P. H., Clark, A. L., & Cleland, J. G. F. (2007) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2007.07211.x · Cited by 58 · see citing works
Role of Statins in Coronary Artery Disease
Lim, S. Y. (2013) · Chonnam Medical Journal · doi:10.4068/cmj.2013.49.1.1 · Cited by 58 · see citing works
Mechanism of action of anti-hypercholesterolemia drugs and their resistance
Tiwari, V., & Khokhar, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.048 · Cited by 59 · see citing works
Statin diabetogenicity: guidance for clinicians
Ray, K. K. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s3 · Cited by 55 · see citing works
Self-citation
Rationale, Design, and Implementation of Aggressive Risk Factor Management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial
Turan, T. N., Lynn, M., Nizam, A., Lane, B. F., Egan, B. M., Le, N., Lopes-Virella, M. F., Hermayer, K. L., Benavente, O., White, C. L., et al. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966911 · Cited by 54 · see citing works
Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina
Niccoli, G., Biasucci, L. M., Biscione, C., Fusco, B., Porto, I., Leone, A. M., Bona, R. D., Dato, I., Liuzzo, G., & Crea, F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.01.009 · Cited by 54 · see citing works
Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients
Roman, R. M., Camargo, P. V. S., Borges, F. K., Rossini, A. P. W., & Polanczyk, C. A. (2010) · Coronary Artery Disease · doi:10.1097/mca.0b013e328333f50d · Cited by 53 · see citing works
Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome
Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303932 · Cited by 53 · see citing works
Effects of statin therapy on progression of mild noncalcified coronary plaque assessed by serial coronary computed tomography angiography: A multicenter prospective study
Li, Z., Hou, Z., Yin, W., Liu, K., Gao, Y., Xu, H., Yu, F., Ma, Z., Yu, W., Yang, L., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.023 · Cited by 47 · see citing works
Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome
Wall, V., Barnhart, S., Kanter, J. E., Kramer, F., Shimizu‐Albergine, M., Adhikari, N., Wight, T. N., Hall, J. L., & Bornfeldt, K. (2018) · JCI Insight · doi:10.1172/jci.insight.96544 · Cited by 46 · see citing works
Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events
Arca, M., & Gaspardone, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00004 · Cited by 46 · see citing works
Early Intervention With Rosuvastatin Decreases the Lipid Components of the Plaque in Acute Coronary Syndrome - Analysis Using Integrated Backscatter IVUS (ELAN Study) -
Otagiri, K., Tsutsui, H., Kumazaki, S., Miyashita, Y., Aizawa, K., Koshikawa, M., Kasai, H., Izawa, A., Tomita, T., Koyama, J., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-0600 · Cited by 43 · see citing works
Statins decrease mean platelet volume irrespective of cholesterol lowering effect
Sıvrı, N., Tekin, G., Yalta, K., Aksoy, Y., Şenen, K., & Yetkın, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0259 · Cited by 41 · see citing works
Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin
Kido, K., Wheeler, M. B., Seratnahaei, A., Bailey, A. L., & Bain, J. A. (2015) · Journal of the American Pharmacists Association · doi:10.1331/japha.2015.14151 · Cited by 38 · see citing works
Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis
Safouris, A., Krogias, C., Sharma, V. K., Katsanos, A. H., Faissner, S., Roussopoulou, A., Zompola, C., Kneiphof, J., Kargiotis, O., Deftereos, S. G., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309292 · Cited by 37 · see citing works
Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Findings from the Moli-sani Study
Bonaccio, M., Castelnuovo, A. F. D., Costanzo, S., Persichillo, M., Curtis, A. D., Cerletti, C., Donati, M. B., de Gaetano, G., & Iacoviello, L. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.117 · Cited by 37 · see citing works
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Geisler, T., Zuern, C. S., Paterok, M., Göhring, K., Bigalke, B., Stellos, K., Seizer, P., Kraemer, B. F., Dippon, J., May, A. E., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn212 · Cited by 37 · see citing works
The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators—A pilot study
Kucera, M., Baláž, D., Kružliak, P., Ciccocioppo, R., Oravec, S., Rodrigo, L., Zulli, A., Hirnerova, E., Sabaka, P., Komorníková, A., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.02.010 · Cited by 35 · see citing works
Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction
Aydın, M. Ü., Aygül, N., Altunkeser, B. B., Ünlü, A., & Taner, A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.003 · Cited by 36 · see citing works
Do structural differences in statins correlate with clinical efficacy?
Arnaboldi, L., & Corsini, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833b776c · Cited by 35 · see citing works
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: Versión resumida
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2008) · Revista Española de Cardiología · Cited by 34 · see citing works
Relation Between Soluble Intercellular Adhesion Molecule-1, Statin Therapy, and Long-Term Risk of Clinical Cardiovascular Events in Patients With Previous Acute Coronary Syndrome (from PROVE IT-TIMI 22)
Ray, K. K., Morrow, D. A., Shui, A. M., Rifai, N., & Cannon, C. P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.04.024 · Cited by 34 · see citing works
Self-citation
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study
Reckless, J. P. D., Henry, P., Pomykaj, T., Lim, S. T., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., Lis, K., Brudi, P., & Allen, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01697.x · Cited by 34 · see citing works

Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology
Ray, K. K., & Cannon, C. P. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200412000-00003 · Cited by 56 · see citing works
Self-citation
Early Time to Benefit with Intensive Statin Treatment: Could It Be the Pleiotropic Effects?
Ray, K. K., & Cannon, C. P. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.027 · Cited by 81 · see citing works
Self-citation
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial
Rouleau, J. L. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.014 · Cited by 47 · see citing works
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320 · see citing works
Evidence-based CARDIOVASCULAR e
Schwartz, G. G., & Singh, D. (2015)

Authors: Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
Monash University (AU)
Harvard University (US)
Guy's Hospital (GB)
Corresponding author: Cannon, Christopher P.
ORCID: Ray, Kausik K.
Cannon, Christopher P.
Tonkin, Andrew M.
Sacks, Frank M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-10
Volume: 46
Issue: 8
Pages: 1405-1410
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.03.077
OpenAlex: W1484156179
Cited by: 356
References: 9
Citations by year: 2026: 10 · 2025: 13 · 2024: 5 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 15 · 2019: 11 · 2018: 17 · 2017: 15 · 2016: 14 · 2015: 11 · 2014: 18 · 2013: 20 · 2012: 24
FWCI: 26.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2845 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: atorvastatin, acute coronary syndrome, high-intensity statin therapy, pravastatin, PROVE IT-TIMI 22, pleiotropy, myocardial infarction, hospital readmission, long-term clinical outcomes
MeSH terms: Atorvastatin, Acute Disease, Angina, Unstable, Double-Blind Method, Female, Heptanoic Acids, Humans, Male, Middle Aged, Myocardial Infarction, Pyrroles, Syndrome, Time Factors, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks